China Dasheng Biotechnology Company (CDBT) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
China Dasheng Biotechnology Company (CDBT), Financial Services sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 38/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 16 Mar 2026China Dasheng Biotechnology Company (CDBT) Finansal Hizmetler Profili
China Dasheng Biotechnology Company, operating within the financial services sector as a shell company, focuses on the production and distribution of bacteria-based additives for livestock feed and crop cultivation in China. The company offers biological bacterium blends and preservatives, serving agricultural and livestock markets.
Yatırım Tezi
China Dasheng Biotechnology Company's investment thesis hinges on its niche market in bacteria-based agricultural additives within China. With a negative P/E ratio of -7.14, the company's profitability is a concern. Key value drivers include expanding its product line and increasing market penetration in the agricultural sector. Growth catalysts involve leveraging its existing distribution network and capitalizing on the demand for sustainable agricultural practices. However, potential risks include the company's OTC listing, which implies lower liquidity and higher volatility, as reflected by its beta of 2.26. Further, the absence of dividends may deter income-seeking investors.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Operates in the financial services sector as a shell company.
- Specializes in bacteria-based products for livestock feed and crop cultivation.
- Based in Lanzhou, China, serving the People's Republic of China market.
- P/E ratio of -7.14 indicates current lack of profitability.
- Beta of 2.26 suggests high volatility compared to the market.
Rakipler & Benzerleri
Güçlü Yönler
- Specialized in bacteria-based agricultural additives.
- Established presence in the Chinese market.
- Offers a range of products for both crop and livestock applications.
- Engages in real estate investment for diversification.
Zayıflıklar
- Negative P/E ratio indicates lack of profitability.
- OTC listing suggests higher risk and lower liquidity.
- Limited geographic diversification outside of China.
- Dependence on the agricultural sector, which can be cyclical.
Katalizörler
- Upcoming: Potential expansion into new geographic markets within China.
- Upcoming: Development and launch of new bacteria-based product lines.
- Ongoing: Increasing demand for sustainable agricultural practices.
- Ongoing: Growing awareness of soil health and the benefits of biological additives.
Riskler
- Potential: Limited financial disclosure due to OTC listing.
- Potential: Lower liquidity and higher price volatility.
- Ongoing: Competition from established agricultural companies.
- Potential: Changes in agricultural regulations and policies.
- Ongoing: Dependence on the agricultural sector, which can be cyclical.
Büyüme Fırsatları
- Expansion into organic farming markets: The growing demand for organic produce presents an opportunity for China Dasheng Biotechnology Company to tailor its products for organic farming practices. The global organic food market is projected to reach $323.1 billion by 2024, offering a substantial market for specialized bacteria-based additives. This expansion could involve developing certifications and formulations that meet organic standards, enhancing market access and brand reputation.
- Development of specialized livestock feed additives: Focusing on developing specialized additives for specific livestock needs, such as poultry or swine, can create a competitive advantage. The global animal feed additives market is projected to reach $27.9 billion by 2027. Tailoring products to address specific nutritional deficiencies or health concerns in livestock can increase product value and customer loyalty.
- Geographic expansion within China: Expanding distribution networks to reach underserved regions within China can significantly increase market penetration. China's agricultural sector is vast and diverse, with varying needs across different provinces. Establishing partnerships with local distributors and agricultural cooperatives can facilitate market entry and build brand awareness in new regions. This targeted approach can capitalize on regional agricultural strengths and address specific local needs.
- Research and development of novel bacterial strains: Investing in research and development to discover and commercialize novel bacterial strains with enhanced efficacy can drive product innovation. The agricultural biotechnology sector is constantly evolving, with new discoveries leading to improved crop yields and disease resistance. Developing proprietary bacterial strains can create a competitive edge and protect market share through patents and intellectual property.
- Strategic partnerships with agricultural technology companies: Collaborating with agricultural technology companies to integrate bacteria-based additives into broader agricultural solutions can enhance market reach and product value. This could involve partnerships with companies specializing in precision farming, data analytics, or irrigation systems. Integrating biological additives into these technologies can create synergistic benefits and provide comprehensive solutions for farmers.
Fırsatlar
- Expansion into organic farming markets.
- Development of specialized livestock feed additives.
- Geographic expansion within China.
- Strategic partnerships with agricultural technology companies.
Tehditler
- Competition from established agricultural companies.
- Changes in agricultural regulations and policies.
- Economic downturns affecting the agricultural sector.
- Potential for product liability claims.
Rekabet Avantajları
- Proprietary bacteria strains and formulations.
- Established distribution network within China.
- Specialized knowledge in bacteria-based agricultural additives.
- Brand recognition in the Chinese agricultural market.
CDBT Hakkında
China Dasheng Biotechnology Company, formerly known as Max Nutrition, Inc., changed its name in March 2008 and is based in Lanzhou, China. The company, along with its subsidiaries, produces, markets, and distributes bacteria-based products used as additives for livestock feed and crop cultivation within the People's Republic of China. Their product line includes artificial microorganisms (AM) and high-efficiency microorganism (HM) based biological bacterium blends, as well as biological preservatives. These products are designed to enhance soil quality, improve nutrient absorption, and reduce diseases in both crops and livestock. Specifically, the company provides AM/HM bacteria-based additives for crops, incorporating components like Bulgaria lactobacillus and beer microzyme. For livestock, the additives soften feed, restrain pathogenic bacteria, and supply beneficial nutrients. Additionally, China Dasheng Biotechnology Company offers FGW bacterial-based preservatives, used for preserving animal specimens and maintaining the freshness of agricultural produce. They also provide bacteria-based fertilizer for plants. The company also engages in residential and commercial real estate investment.
Ne Yaparlar
- Produces bacteria-based additives for livestock feed.
- Manufactures bacteria-based additives for crop cultivation.
- Offers artificial microorganism (AM) based products.
- Provides high-efficiency microorganism (HM) based products.
- Distributes biological bacterium blends.
- Supplies biological preservatives.
- Engages in residential and commercial real estate investment.
İş Modeli
- Sells bacteria-based additives directly to farmers and agricultural businesses.
- Distributes products through a network of distributors and retailers.
- Generates revenue from the sale of biological preservatives.
- Derives income from real estate investments.
Sektör Bağlamı
China Dasheng Biotechnology Company operates within the agricultural biotechnology sector, which is influenced by trends towards sustainable farming and increasing demand for higher crop yields. The competitive landscape includes companies offering similar biological additives and fertilizers. The market is driven by the need for environmentally friendly solutions and the growing awareness of soil health. China's agricultural sector is a significant market, but competition is intense with both domestic and international players vying for market share.
Kilit Müşteriler
- Farmers cultivating various crops.
- Livestock producers raising animals for meat and dairy.
- Agricultural businesses involved in crop and livestock production.
- Scientific research institutions requiring animal specimen preservation.
- Real estate tenants (residential and commercial).
Finansallar
Grafik & Bilgi
China Dasheng Biotechnology Company (CDBT) hisse senedi fiyatı: Price data unavailable
Son Haberler
CDBT için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
CDBT için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
CDBT için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, CDBT'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Sınıflandırma
Sektör Shell CompaniesYönetim: Gang Chen
CEO
Gang Chen is the CEO of China Dasheng Biotechnology Company, leading a team of 689 employees. Information on his detailed career history, education, and previous roles is not available in the provided data. His leadership is pivotal in guiding the company's strategic direction and operational execution within the agricultural biotechnology sector.
Sicil: Due to limited information, specific achievements, strategic decisions, and company milestones under Gang Chen's leadership cannot be detailed. His role involves overseeing the production, marketing, and distribution of bacteria-based products for livestock feed and crop cultivation.
CDBT OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that China Dasheng Biotechnology Company may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and the trading of their securities can be highly speculative. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, leading to increased risks for investors.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure due to OTC Other listing.
- Lower liquidity and wider bid-ask spreads.
- Higher price volatility compared to exchange-listed stocks.
- Potential for delisting or trading suspension due to non-compliance.
- Increased risk of fraud or manipulation due to less regulatory oversight.
- Verify the company's financial statements and audit reports.
- Assess the company's business operations and revenue streams.
- Investigate the background and experience of the company's management team.
- Review the company's legal and regulatory filings.
- Evaluate the company's competitive position and market share.
- Determine the level of trading volume and liquidity.
- Consult with a financial advisor to assess the risks and potential rewards.
- Operational business with products and services in the agricultural sector.
- Presence in the Chinese market with a focus on bacteria-based additives.
- Existence of a management team and employees.
- Company history dating back to its initial incorporation as Max Nutrition, Inc.
China Dasheng Biotechnology Company Hissesi: Cevaplanan Temel Sorular
CDBT için değerlendirilmesi gereken temel faktörler nelerdir?
China Dasheng Biotechnology Company (CDBT) şu anda yapay zeka skoru 38/100, düşük puanı gösteriyor. Temel güçlü yan: Specialized in bacteria-based agricultural additives.. İzlenmesi gereken birincil risk: Potential: Limited financial disclosure due to OTC listing.. Bu bir finansal tavsiye değildir.
CDBT MoonshotScore'u nedir?
CDBT şu anda MoonshotScore'da 38/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
CDBT verileri ne sıklıkla güncellenir?
CDBT fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler CDBT hakkında ne diyor?
CDBT için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
CDBT'a yatırım yapmanın riskleri nelerdir?
CDBT için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Limited financial disclosure due to OTC listing.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
CDBT'ın P/E oranı nedir?
CDBT için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için CDBT'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
CDBT aşırı değerli mi, yoksa düşük değerli mi?
China Dasheng Biotechnology Company (CDBT)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
CDBT'ın temettü verimi nedir?
China Dasheng Biotechnology Company (CDBT) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Limited information available due to OTC listing and disclosure status.
- AI analysis pending, which may provide further insights.